Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Bromide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.74 |
| ▸ | P2RY2 | P41231 | 15/20 | 0.67 |
| ▸ | P2RY4 | P51582 | 11/20 | 0.67 |
| ▸ | P2RY6 | Q15077 | 8/20 | 0.67 |
| ▸ | POLA1 | P09884 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20798009 | 0.99 | DUT (0.75) | DUTP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL12729520 | 0.99 | DUT (0.75) | DUTP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL8003 | 0.99 | DUT (0.75) | DUTP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL48209 | 0.99 | DUT (0.75) | DUTP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL20074354 | 0.99 | DUT (0.75) | DUTP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL27554036 | 0.99 | DUT (0.75) | DUTP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL16633413 | 0.99 | DUT (0.75) | DUTP2RY2P2RY4P2RY6POLA1 | |
| SCHEMBL2349191 | 0.99 | DUT (0.75) | DUTP2RY2P2RY4P2RY6POLA1 | |
| Iodide SCHEMBL7941539 | 0.98 | DUT (0.74) | DUTP2RY2P2RY4P2RY6POLA1 | |
| Water SCHEMBL3961110 | 0.98 | DUT (0.74) | DUTP2RY2P2RY4P2RY6POLA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3277692-B1 | COUMARIN DERIVATIVE AS ANTIVIRAL AGENT, PHARMACEUTICAL COMPOSITION THEREOF, ITS PREPARATION AND USE | I NOVA MEDICINSKA ISTRAZIVANJA D O O (HR) | 2019-09-11 | — | — | EP | disclosed |
| US-10266545-B2 | Coumarin derivative as antiviral agent, pharmaceutical composition thereof, its preparation and use | I-NOVA MEDICINSKA ISTRAZIVANJA D.O.O. (HR) | 2019-04-23 | — | — | US | disclosed |
| US-20180072752-A1 | COUMARIN DERIVATIVE AS ANTIVIRAL AGENT, PHARMACEUTICAL COMPOSITION THEREOF, ITS PREPARATION AND USE | I-NOVA MEDICINSKA ISTRAZIVANJA D.O.O. (HR) | 2018-03-15 | — | — | US | disclosed |
| EP-3277692-A1 | COUMARIN DERIVATIVE AS ANTIVIRAL AGENT, PHARMACEUTICAL COMPOSITION THEREOF, ITS PREPARATION AND USE | I-nova Medicinska Istrazivanja d.o.o. (HR) | 2018-02-07 | — | — | EP | disclosed |
| WO-2016156888-A1 | COUMARIN DERIVATIVE AS ANTIVIRAL AGENT, PHARMACEUTICAL COMPOSITION THEREOF, ITS PREPARATION AND USE | I-NOVA MEDICINSKA ISTRAZIVANJA D.O.O. (HR) | 2016-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180072752-A1 | COUMARIN DERIVATIVE AS ANTIVIRAL AGENT, PHARMACEUTICAL COMPOSITION THEREOF, ITS PREPARATION AND USE | CYP3A7, MAVS, SARS1 | DUT 253/4885P2RY2 3325/4885P2RY4 2111/4885 |
| US-10266545-B2 | Coumarin derivative as antiviral agent, pharmaceutical composition thereof, its preparation and use | CYP3A7, MAVS, SARS1 | DUT 253/4885P2RY2 3325/4885P2RY4 2111/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.